MARKET

SCNX

SCNX

Scienture Holdings, Inc
NASDAQ
0.3454
+0.0014
+0.41%
After Hours: 0.3454 0 0.00% 16:10 07/06 EDT
OPEN
0.3510
PREV CLOSE
0.3440
HIGH
0.3700
LOW
0.3355
VOLUME
160.48K
TURNOVER
--
52 WEEK HIGH
2.600
52 WEEK LOW
0.2382
MARKET CAP
14.03M
P/E (TTM)
-0.1526
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SCNX last week (0629-0703)?
Weekly Report · 11h ago
Weekly Report: what happened at SCNX last week (0622-0626)?
Weekly Report · 06/29 09:32
Weekly Report: what happened at SCNX last week (0615-0619)?
Weekly Report · 06/22 09:36
Scienture announces progress in commercialization of Arbli
TipRanks · 06/18 12:30
Scienture Announces Progress Towards Commercialization Of Its Arbli Oral Suspension Including Expanded Payor Coverage, Broader Pharmacy Access And New Channel Partnerships
Benzinga · 06/18 12:13
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
Barchart · 06/18 07:05
Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and Scienture Holdings (SCNX)
TipRanks · 06/16 16:40
Weekly Report: what happened at SCNX last week (0608-0612)?
Weekly Report · 06/15 09:37
More
About SCNX
Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.

Webull offers Scienture Holdings Inc stock information, including NASDAQ: SCNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SCNX stock methods without spending real money on the virtual paper trading platform.